secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001104659-22-024468
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances
--------------------------------------------------------------------------------

- FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).
- Adjusted EBITDA $234M; year-end cash $620M.
- Non-GAAP diluted EPS $1.16 vs $0.79 in FY2020; Q4 Non-GAAP EPS $0.27.
- Initiated clinical studies for IW-3300 (visceral pain) and CNP-104 (primary biliary cholangitis).
- LINZESS U.S. net sales exceeded $1B in 2021, achieving blockbuster status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/0001104659-22-024468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/tm226866d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-024468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer